KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Moderna (MRNA) EBIT (2017 - 2026)

Moderna (MRNA) has disclosed EBIT for 10 consecutive years, with -$1.4 billion as the latest value for Q1 2026.

  • For Q1 2026, EBIT fell 32.19% year-over-year to -$1.4 billion; the TTM value through Mar 2026 reached -$3.4 billion, up 8.5%, while the annual FY2025 figure was -$3.1 billion, 22.08% up from the prior year.
  • EBIT hit -$1.4 billion in Q1 2026 for Moderna, down from -$857.0 million in the prior quarter.
  • Across five years, EBIT topped out at $4.2 billion in Q1 2022 and bottomed at -$2.0 billion in Q3 2023.
  • Average EBIT over 5 years is -$189.8 million, with a median of -$857.0 million recorded in 2025.
  • Year-over-year, EBIT soared 233.89% in 2022 and then tumbled 20866.67% in 2024.
  • Moderna's EBIT stood at $1.6 billion in 2022, then crashed by 99.62% to $6.0 million in 2023, then crashed by 20866.67% to -$1.2 billion in 2024, then skyrocketed by 31.22% to -$857.0 million in 2025, then tumbled by 61.96% to -$1.4 billion in 2026.
  • According to Business Quant data, EBIT over the past three periods came in at -$1.4 billion, -$857.0 million, and -$260.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.